-

Tandem Diabetes Care to Announce First Quarter 2021 Financial Results on May 5, 2021

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2021 results after the financial markets close on Wednesday, May 5, 2021. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its first quarter 2021 financial and operating results.

Conference Call/Webcast Details:
Date:
May 5, 2021
Time: 4:30 pm Eastern Time (1:30 pm Pacific Time)
Toll Free Dial-In Number: (855) 427-4396
International Dial-In Number: (484) 756-4261
Conference ID: 8046918
Webcast Link: https://edge.media-server.com/mmc/p/tz4ptaur

An archive of the webcast will be available for 30 days following the event on Tandem Diabetes Care’s Investor Center website located at http://investor.tandemdiabetes.com in the “Events & Presentations” section.

About Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical device company dedicated to improving the lives of people with diabetes through relentless innovation and revolutionary customer experience. The Company takes an innovative, user-centric approach to the design, development and commercialization of products for people with diabetes who use insulin. Tandem’s flagship product, the t:slim X2™ insulin pump, is capable of remote software updates using a personal computer and features integrated continuous glucose monitoring, and optional automated insulin delivery technology. Tandem is based in San Diego, California.

Follow Tandem Diabetes Care on Twitter @tandemdiabetes, use #tslimX2 and $TNDM.
Follow Tandem Diabetes Care on Facebook at www.facebook.com/TandemDiabetes.
Follow Tandem Diabetes Care on LinkedIn at www.linkedin.com/company/TandemDiabetes.

Tandem Diabetes Care is a registered trademark and t:slim X2 is a trademark of Tandem Diabetes Care, Inc.

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com

Tandem Diabetes Care

NASDAQ:TNDM

Release Versions
$Cashtags

Contacts

Media Contact:
Steve Sabicer
714-907-6264
ssabicer@thesabicergroup.com

Investor Contact:
Susan Morrison
858-366-6900 x7005
smorrison@tandemdiabetes.com

Social Media Profiles
More News From Tandem Diabetes Care

Tandem Diabetes Care Launches t:slim X2 Insulin Pump Compatibility with Abbott FreeStyle Libre 3 Plus Sensor in Five International Markets

SAN DIEGO--(BUSINESS WIRE)--The t:slim X2™ insulin pump from Tandem Diabetes Care is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM sensor in five EU countries....

Tandem Diabetes Care to Announce Second Quarter 2026 Financial Results on August 6, 2026

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its second quarter 2026 results after the financial markets close on Thursday, August 6, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its second quarter 2026 financial and operating results.A live webcast of the call will be available on Tandem Diabet...

Tandem Diabetes Care Automated Insulin Delivery Systems Receive CE Mark for Type 2 Diabetes and Type 1 Diabetes During Pregnancy

SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care receives CE mark for AID systems in Europe to include use in type 1 diabetes during pregnancy and adults with type 2 diabetes....
Back to Newsroom